Release date: October 2011
Termination date: October 2012
OVERVIEW OF ACTIVITY
Lung cancer accounts for more cancer-related deaths among both men and women than any other tumor type. Despite the recent advances in the development of several molecular-targeted therapies, their full utility will be realized only through the effective identification of biomarkers predictive of disease response and, ultimately, patient benefit. This unique educational activity delivers highly applicable, current clinical information delving into the personalized management of this challenging disease and provides clinicians with a concise, easy-to-understand slide resource to facilitate knowledge and application of optimal diagnostic and therapeutic approaches.
TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.
LEARNING OBJECTIVES
- Effectively integrate available EGFR and VEGF inhibitors into the evidence-based treatment of non-small cell lung cancer (NSCLC).
- Identify clinical and histologic characteristics of ineligibility for or intolerance or resistance to existing anti-angiogenic therapy, and apply them to clinical decision-making with regard to the use of bevacizumab in the treatment of advanced NSCLC.
- Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors (TKIs), and identify investigational therapeutic opportunities to circumvent this process.
- Appreciate the clinical significance of the EML4-ALK fusion gene, and recall emerging data with ALK inhibitors in the affected population with NSCLC.
- Assess new oncogenic pathways mediating the growth of unique NSCLC tumor subsets, and recall emerging data with experimental agents exploiting these targets.
- Counsel appropriately selected patients with NSCLC for participation in ongoing pivotal clinical trials.
ACCREDITATION STATEMENT
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Albert Einstein College of Medicine designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at www.ResearchToPractice.com/CESL_LC11/Video/CME.
DISCLOSURE POLICY
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Albert Einstein College of Medicine, CCME and Research To Practice staff have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
DISCLAIMER
The opinions expressed herein are those of the authors and do not necessarily represent the views of the Albert Einstein College of Medicine (sponsor), Research To Practice (co-sponsor) or Boehringer Ingelheim, Genentech and Bayer/Onyx (supporters). Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
This CME activity was planned and produced in accordance with the ACCME Essentials.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
John Heymach, MD, PhD
Associate Professor of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consultant: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline, Pfizer Inc; Grant/Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Pfizer Inc.
Thomas J Lynch Jr, MD
Jonathan and Richard Sackler Professor of Internal Medicine
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut
Consultant: Boehringer Ingelheim Pharmaceuticals Inc, Merck and Company Inc, SuperGen Inc; Stockholder: Infinity Pharmaceuticals Inc.
Vincent A Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Consultant: ArQule, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly USA LLC, OSI Pharmaceuticals Inc, Sanofi; Grant/Research: Boehringer Ingelheim Pharmaceuticals Inc, Lilly USA LLC, Sanofi.
Tony SK Mok, MD
Professor, Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China
Consultant: AstraZeneca Pharmaceuticals LP, Merck Serono, Roche Laboratories Inc, Taiho Pharmaceutical Co Ltd; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Lilly USA LLC, Roche Laboratories Inc.
Roman Perez-Soler, MD (Course Director)
Guttman Professor of Medicine
Chair, Department of Oncology
Montefiore Medical Center
Chief, Division of Medical Oncology
Associate Director for Clinical Research
Albert Einstein Cancer Center
Bronx, New York
Consultant and Speakers Bureau: Genentech BioOncology, Lilly USA LLC, Roche Laboratories Inc.
RESEARCH TO PRACTICE — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
OFF-LABEL/INVESTIGATIONAL DISCLOSURES
Dr Miller intends to discuss crizotinib and erlotinib as part of his presentation.
This activity has been made possible (in part) by unrestricted educational grants from Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Boehringer Ingelheim Pharmaceuticals Inc and Genentech BioOncology & OSI Oncology.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio